News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN) Talks to Buy Onyx Pharmaceuticals, Inc. (ONXX) Said to Stall on Drug Trial Data


8/15/2013 7:20:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Buyout talks over Amgen Inc. (AMGN)’s proposed takeover of Onyx Pharmaceuticals Inc. (ONXX) are held up over a dispute about access to data from an ongoing drug trial even as the two sides have a general agreement on price, said three people familiar with the matter. Onyx is prepared to accept a $130-a-share all-cash offer and Amgen remains interested, the people said. At issue is whether Onyx will provide Amgen with data from a study designed for European approval of Onyx’s blood-cancer treatment Kyprolis, said two of the people, who asked not to be named because the discussions are private.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES